Revance Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Revance Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Revance Therapeutics Inc Strategy Report
- Understand Revance Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Revance Therapeutics Inc (Revance Therapeutics) is a biotechnology company that focuses on the development, manufacturing and marketing novel botulinum toxin products. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Through the acquisition of HintMD, the company uses it platform to engage in the smart payment solution to process payments for their patients and provides subscription and pay-over-time solutions that support practices for the aesthetic treatment plans. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.
Headquarters
United States of America
Address
1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
Website
www.revance.com
Telephone
1 615 7247755
No of Employees
534
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RVNC (NASD)
Revenue (2022)
$234.0M
76.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
9.1%
(2022 vs 2021)
Market Cap*
$391.9M
Net Profit Margin (2022)
XYZ
48.5%
(2022 vs 2021)
* As of and is in US$
Revance Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline Portfolio: | HintMD Platform: | Revance |
| DaxibotulinumtoxinA: | Smart Payment Solution | RHA |
| Chronic Migraine | OPUL | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Revance Therapeutics Inc | Viatris Inc | Alimera Sciences Inc | Allergan Ltd | Anthera Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Ireland | United States of America |
| City | Nashville | Canonsburg | Alpharetta | Dublin | Hayward |
| State/Province | Tennessee | Pennsylvania | Georgia | Leinster | California |
| No. of Employees | 534 | 38,000 | 159 | - | 21 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Angus C. Russell | Chairman | Executive Board | 2014 | 67 |
| Mark J. Foley | Chief Executive Officer; Director; President | Executive Board | 2019 | 57 |
| Tobin C. Schilke | Chief Financial Officer | Senior Management | 2018 | 48 |
| David A. Hollander, M.D | Chief Medical Officer | Senior Management | 2022 | - |
| Dustin S. Sjuts | President | Senior Management | 2021 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward